Validation Data Gallery
Tested Applications
Recommended dilution
| Application | Dilution |
|---|---|
| It is recommended that this reagent should be titrated in each testing system to obtain optimal results. | |
| Sample-dependent, Check data in validation data gallery. | |
Published Applications
| WB | See 1 publications below |
Product Information
11748-1-AP targets PI3 kinase p85 Alpha in WB, ELISA applications and shows reactivity with human, mouse, rat samples.
| Tested Reactivity | human, mouse, rat |
| Cited Reactivity | mouse |
| Host / Isotype | Rabbit / IgG |
| Class | Polyclonal |
| Type | Antibody |
| Immunogen | PI3 kinase p85 Alpha fusion protein Ag2344 相同性解析による交差性が予測される生物種 |
| Full Name | phosphoinositide-3-kinase, regulatory subunit 1 (alpha) |
| Calculated molecular weight | 85 kDa |
| GenBank accession number | BC030815 |
| Gene Symbol | PI3 Kinase p85 Alpha |
| Gene ID (NCBI) | 5295 |
| Conjugate | Unconjugated |
| Form | Liquid |
| Purification Method | Antigen affinity purification |
| UNIPROT ID | P27986 |
| Storage Buffer | PBS with 0.02% sodium azide and 50% glycerol , pH 7.3 |
| Storage Conditions | Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage. |
Background Information
Phosphatidylinositol 3-kinase (PI3K) plays an important role in the metabolic actions of INS and is required for adipogenesis. The PI3K pathway has also been identified as an important player in cancer development and progression. The Class IA PI3K heterodimer, which is composed of a P110 catalytic subunit and a P85 regulatory subunit, is activated upon association of the P85 subunit with upstream adaptor proteins or receptor tyrosine kinases. Mutations in PIK3R1 are implicated in cases of breast cancer and associated to SHORT syndrome.
Publications
| Species | Application | Title |
|---|---|---|
J Nanobiotechnology Delivery of engineered extracellular vesicles with miR-29b editing system for muscle atrophy therapy. |